爱尔眼科：公司专注眼科医疗，持续关注多学科交叉前沿领域发展

证券之星08-04

证券之星消息，爱尔眼科(300015)08月04日在投资者关系平台上答复投资者关心的问题。

投资者提问：贵司作为专业眼科头部企业，现在最前沿的通过脑机接口帮助视力残障人士重现光明的人脑工程研发居然没有任何介入？

爱尔眼科回复：谢谢关注。公司专注眼科医疗，持续关注多学科交叉前沿领域发展。

本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。

相关 ETF

责任编辑：陈思雨

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/2656208538?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-08-04 15:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2656208538","market":"fut","top_or_hot":-1,"title":"爱尔眼科：公司专注眼科医疗，持续关注多学科交叉前沿领域发展","media":"证券之星","content":"<html><body><p>证券之星消息，<a href=\"https://laohu8.com/S/300015\">爱尔眼科</a>(300015)08月04日在投资者关系平台上答复投资者关心的问题。</p><p>投资者提问：贵司作为专业眼科头部企业，现在最前沿的通过脑机接口帮助视力残障人士重现光明的人脑工程研发居然没有任何介入？</p><p>爱尔眼科回复：谢谢关注。公司专注眼科医疗，持续关注多学科交叉前沿领域发展。</p><p>本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。</p><h2>相关 ETF</h2><p><img src=\"https://static.stockstar.com/etf/15936120260803.png\"/><img src=\"https://static.stockstar.com/etf/58808020260803.png\"/><img src=\"https://static.stockstar.com/etf/58827020260803.png\"/><img src=\"https://static.stockstar.com/etf/51201020260803.png\"/></p><p>责任编辑：陈思雨</p></body></html>","source":"stockstar","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>爱尔眼科：公司专注眼科医疗，持续关注多学科交叉前沿领域发展</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n爱尔眼科：公司专注眼科医疗，持续关注多学科交叉前沿领域发展\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-08-04 15:18 北京时间&nbsp;&nbsp;&nbsp;<a href=https://stock.stockstar.com/RB2026080400020178.shtml><strong>证券之星</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>证券之星消息，爱尔眼科(300015)08月04日在投资者关系平台上答复投资者关心的问题。投资者提问：贵司作为专业眼科头部企业，现在最前沿的通过脑机接口帮助视力残障人士重现光明的人脑工程研发居然没有任何介入？爱尔眼科回复：谢谢关注。公司专注眼科医疗，持续关注多学科交叉前沿领域发展。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。相关 ETF责任编辑：陈思雨</p>\n\n<a href=\"https://stock.stockstar.com/RB2026080400020178.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0096","symbol_name":"民营医院","start_time":0,"source_url":"https://stock.stockstar.com/RB2026080400020178.shtml","article_id":"2656208538","we_media_id":"1082532455","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2656208538","pubTimestamp":1785827901,"columns":[],"sourceInfo":{"source_id":"stockstar","name":"证券之星"},"weMediaInfo":{"media_name":"证券之星","introduction":"证券之星始创于1996年，是国内领先的金融信息及综合服务平台。关注证券之星，即时获取有价值的财经资讯。","home_visible":1,"id":"1082532455","head_image":"https://community-static.tradeup.com/news/2e305640fc27210243042d09d3a7fa3f"},"summary":"证券之星消息，爱尔眼科(300015)08月04日在投资者关系平台上答复投资者关心的问题。投资者提问：贵司作为专业眼科头部企业，现在最前沿的通过脑机接口帮助视力残障人士重现光明的人脑工程研发居然没有任何介入？爱尔眼科回复：谢谢关注。公司专注眼科医疗，持续关注多学科交叉前沿领域发展。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。相关 ETF责任编辑：陈思雨","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"300015":"爱尔眼科","BK0096":"民营医院","LU1820825898.SGD":"Aberdeen Standard SICAV I - China A Share Equity A Acc SGD-H","BK0236":"卫生","BK0188":"融资融券","BK0012":"证金概念","BK0114":"健康中国","BK0200":"360概念","BK0077":"质押式回购","BK0196":"行业龙头","LU0979878070.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"A\" (USD) ACC","LU1242518857.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"I\" (USD) ACC","BK0028":"国家队","BK0113":"养老产业","LU1146622755.USD":"安本中国A股股票基金A Acc","LU1242518931.SGD":"Fullerton Lux Funds - Asia Absolute Alpha A Acc SGD"},"translate_title":"Aier Ophthalmology: The company focuses on ophthalmology and continues to pay attention to the development of multi-disciplinary cross-cutting frontier fields","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300015":1.5},"content_text":"证券之星消息，爱尔眼科(300015)08月04日在投资者关系平台上答复投资者关心的问题。投资者提问：贵司作为专业眼科头部企业，现在最前沿的通过脑机接口帮助视力残障人士重现光明的人脑工程研发居然没有任何介入？爱尔眼科回复：谢谢关注。公司专注眼科医疗，持续关注多学科交叉前沿领域发展。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。相关 ETF责任编辑：陈思雨","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2656208538","isCrawlerRequest":true}